Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term chemotherapy. Found 241 abstracts

no pagination
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016 May;122(9):1349-69.
Esnaola NF, Meyer JE, Karachristos A, Maranki JL, Camp ER, Denlinger CS. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer. 2016 May;122(9):1349-69.
Rice TW, Lerut TE, Orringer MB, Chen LQ, Hofstetter WL, Smithers BM, Rusch VW, van Lanschot J, Chen KN, Davies AR, D'Journo XB, Kesler KA, Luketich JD, Ferguson MK, Rasanen JV, van Hillegersberg R, Fang W, Durand L, Allum WH, Cecconello I, Cerfolio RJ, Pera M, Griffin SM, Burger R, Liu JF, Allen MS, Law S, Watson TJ, Darling GE, Scott WJ, Duranceau A, Denlinger CE, Schipper PH, Ishwaran H, Apperson-Hansen C, DiPaola LM, Semple ME, Blackstone EH. Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2016 Oct;29(7):715-23.
Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016 Oct 22;172(2):208-18.   PMCID: PMC4710555
Wang HH, Zaorsky NG, Meng MB, Wu ZQ, Zeng XL, Jiang B, Jiang C, Zhao LJ, Yuan ZY, Wang P. Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma. Onco Targets Ther. 2015 Jan;8:437-44.   PMCID: Pmc4335610
Zhang Y, Wang J, Xie J, Yang D, Han G, Zhang Y, Fu Q. The assay and clinical significance of serum thymidine kinase 1 in patients with colorectal carcinoma. Eur Surg. 2015 Oct;47(5):248-53.
Zhao YZ, Chen LJ, Lin Q, Cai J, Yu WZ, Zhao YP, Xu CY, Mao KL, Tian FR, Li WF, Wong HL, Lu CT. Using FUS induced BBB/BTB-opening technique combined with Doxorubicin liposomes to improve glioma-targeted inhibition. Oncotarget. 2015 Sep 02;.
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8.   PMCID: No NIH funds
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, MacDonald J, Willett CG. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 <= 90 U/mL and Comparison to the CONKO-001 Trial. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(3):E291-E297.
Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB, MacDonald J, Willett CG. Five Year Results of US Intergroup/RTOG 9704 With Postoperative CA 19-9 <= 90 U/mL and Comparison to the CONKO-001 Trial. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(3):E291-E297.
Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD, Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Science. 2012 Aug;103(8):1531-7.   PMCID: PMC3407321[Available on 2013/8/1]
Coleman RL, Sill MW, Lankes HA, Fader AN, Finkler NJ, Hoffman JS, Rose PG, Sutton GP, Drescher CW, McMeekin DS, Hu W, Deavers M, Godwin AK, Alpaugh RK, Sood AK. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Dec;127(3):538-43.   PMCID: PMC3568489
Colt DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):366-400.   PMCID: not NIH funded
Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck M, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant Pleural Mesothelioma. Journal of the National Comprehensive Cancer Network. 2012 Jan;10(1):26-41.   PMCID: not NIH funded
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
Gillet JP, Calcagno AM, Varma S, Davidson B, Elstrand MB, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, Gottesman MM. Multidrug Resistance-Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma. Clinical Cancer Research. 2012 Jun;18(11):3197-206.   PMCID: PMC3376649
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology. 2012 May;23(5):1144-50.   PMCID: *
Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology. 2012 Apr;17(2):96-104.   PMCID: *
Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 2012 Apr;18(7):2056-65.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term chemotherapy

chemotherapy survival radiotherapy surgery progression gemcitabine expression radiation therapy resectable pancreatic-cancer transplantation carcinoma chemoradiation breast-cancer markers doxorubicin cisplatin cancer diagnosis Neoplasm Staging randomized extrahepatic endoscopy NCCN Guidelines cell lung-cancer NCCN Clinical Practice Guidelines serum intrahepatic adenocarcinoma positron-emission-tomography ca-19-9 cholangiocarcinoma trial therapy randomized controlled-trial curative resection pathology Overall survival phase-iii controlled-trial Endometrial cancer Aflibercept-VEGF Trap-Toxicity-Fibroblast growth factor multicenter phase-ii combination phase-ii microarray Male subfamily-b member-1 adverse effects lymph node dissection prognosis marker Female bladder-cancer focused ultrasound intensity-modulated radiotherapy HER2 circulating tumor cells-immunohistochemical subtypes-metastatic breast cancer-tumor markers Kaplan-Meier Estimate plus cetuximab dose-escalation Breast neoplasm Circulating tumor cell-HER2-Metastasis recombinant interleukin-2 therapy phase-iii trial Lung Neoplasms mantle cell lymphoma biweekly cetuximab braf mutations expression profiles pemetrexed plus cisplatin platinum-containing Progression-free survival at 6 months Intrahepatic Bile Ducts 1993 n jkl-journal of dermatologic surgery and oncology-v19-p985 gene amplification metastatic metastases braf(v600e) mutation stage-i skin Middle Aged blood trimodality therapy vegf maintenance therapy mrp7 lymphoma kinase kinase-1 Second-line treatment esophageal neoplasm drug-resistance system mortality pleural effusion isolated limb perfusion colorectal carcinoma Non-Small-Cell Lung Carcinoma stage-iii melanoma vinflunine Proportional Hazards Models Tumor Biomarkers phosphodiesterase-5 erectile ptc Diagnostic Imaging 2 inhibitor transitional-cell carcinoma Paclitaxel cancer staging etiology Imidazoles Treatment Outcome Bile Duct Neoplasms interferon sentinel lymph node abcc10 methods growth-factor receptor Indazoles cooperative-oncology-group Bevacizumab cell-death primary cutaneous melanoma tumors adjuvant therapy proteasome inhibition asbestos irinotecan mesothelioma potentiating factor ca-15-3 bnip3 non-squamous paclitaxel multicenter Intermediate endpoint megakaryocyte margin Neutropenia non-small-cell lung cancer bevacizumab extrapleural pneumonectomy Antineoplastic Combined Chemotherapy Protocols follow-up selectivity Advanced urothelial carcinoma tract Carboplatin high-risk melanoma chemically induced peripheral-blood tumor marker bcl-2 family
Last updated on Monday, May 04, 2020